Per Bengtsson appointed CEO

Per Bengtsson appointed CEO

STOCKHOLM, October 24, 2011 - The Board of Directors in Karo Bio AB
(publ) has appointed Per Bengtsson, CEO. Per Bengtsson has been acting
CEO and member of the Board since May.

“Karo Bio is facing several major challenges that beyond niche expertise
also places high demands on commercial ability. Per knows Karo Bio well
and has this competence, so we are delighted that he has accepted the
challenge,” says Chairman of the Board Göran Wessman.
“In parallel with the Phase III program for eprotirome, Karo Bio has
interesting and promising development projects which are attracting
great interest. My goal is to highlight values within the company and to
create optimal conditions for commercial success,” says Per Bengtsson.
Per Bengtsson is a licensed physician and doctor of medicine (PhD). He
began his career in biotech as a medical officer and project manager at
Karo Bio in the early 1990's. He has since then been Medical Director
and Therapeutic Area Head at Ferring, CEO of Probi AB (publ), Head of
R&D at Pharmacia/Pharmacia & Upjohn Plasma Products, and Development
Manager at Bionor Immuno A/S.
 
For further information, please contact:
Göran Wessman, Chairman, phone: +46 708 16 14 50

About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and
development of innovative drugs for large medical needs. The company
runs a number of drug development projects within the indication areas
cardiovascular and metabolic diseases, neuropsychiatry, inflammation,
autoimmune diseases, cancer and women's health. An important foundation
for the company's activities is its unique knowledge of nuclear
receptors as target proteins for the development of novel
pharmaceuticals, as well as related mechanisms of action. Karo Bio is
based in Huddinge, Sweden, has around 70 employees and is listed on
NASDAQ OMX Stockholm.

Karo Bio publishes this information in accordance with the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading
Act. The information was published on 24 October, 2011, at 08:30 am CET.

This press release is also available online at
www.karobio.com (http://www.karobio.com/) and www.newsroom.cision.com